 "An employee works at the reception area of Cipla at its headquarters in Mumbai")
Drug major Cipla has inked a pact with US-based BioQ Pharma for registration and commercialisation of latter's Ropivacaine infusion system, used in treating post-operative pain, in India.
BioQ Pharma and Cipla have inked a strategic distribution, supply and development agreement for the registration and commercialisation of BioQ Pharma's Ropivacaine infusion pharmaceutical in India, the companies said in a joint statement.
"We believe this innovative product represents a significant evolution in enhancing the delivery of infusions and managing post-surgical pain," Cipla's India Business Head, Nikhil Chopra said.
BioQ Pharma's unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care.
ALSO READ: Cipla launches hepatitis C drug Hepcvir-L
In particular, the Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution.
BioQ Pharma, President and CEO, Josh Kriesel said the company is excited to collaborate with Cipla and expand its worldwide commercial footprint into India.
"We believe India is an excellent market to help expand our objective of establishing a new standard of care in the presentation and administration of infusible pharmaceuticals," he added.
Cipla's proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma's proprietary unit-dose, large volume infusion pharmaceuticals to India's healthcare market, Kriesel said.
